SkinMedica, Inc.

SkinMedica, Inc. is a skincare company specializing in advanced formulations that leverage growth factor technology to effectively address aging, skin texture, and pigmentation concerns. SkinMedica, Inc. was founded in 1999 in Carlsbad, US, focusing on developing skincare products that utilize growth factor technology.

In November 2012, Allergan Inc. acquired SkinMedica for USD 375 mn, comprising USD 350 mn upfront and an additional USD 25 mn contingent upon revenue milestones. The company has participated in 10 deals since its inception. SkinMedica® specializes in advanced skincare products that leverage growth factor technology to address various skin concerns related to aging, texture, and pigmentation.

Their flagship products include TNS® Advanced+ Serum, HA⁵® Rejuvenating Hydrator, and Even & Correct Advanced Brightening Treatment, all designed to promote skin rejuvenation, hydration, and even skin tone. These products utilize clinically studied ingredients aimed at improving skin elasticity, reducing fine lines, and enhancing overall skin appearance. SkinMedica® serves a diverse clientele that includes dermatologists, aesthetic professionals, and consumers seeking effective skincare solutions. The company markets its products primarily in North America, with an expanding footprint in international markets, targeting regions with a growing demand for premium skincare solutions.

SkinMedica® generates revenue through direct sales and partnerships with healthcare professionals and retailers. The company operates primarily on a B2B model, supplying products to dermatologists and medical spas, while also providing direct-to-consumer sales through their official website. Revenue is driven by a range of individual products, with pricing reflecting their premium positioning in the skincare market. For example, the TNS® Advanced+ Serum and HA⁵® Rejuvenating Hydrator are flagship offerings, priced at USD 295 and USD 192 respectively.

The structured transactions often involve bulk orders from clinics and subscription services for automatic product replenishment, ensuring consistent revenue streams while catering to the ongoing skincare needs of their clients. Following the acquisition by Allergan in November 2012, SkinMedica plans to leverage the new resources to launch additional products targeting niche segments of the skincare market. The company is also looking to expand its presence in international markets, particularly in Europe and Asia, by 2025. The funding from the acquisition will be utilized to support product development and market entry strategies, aiming to enhance their global footprint while meeting the increasing demand for innovative skincare solutions.